# Jazz Pharmaceuticals

Source: https://onco.cc/companies/jazz/  
OnCo record `jazz` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jazz Pharmaceuticals, based in Dublin, sells zanidatamab (Ziihera), a HER2-targeting antibody, outside Asia for biliary tract and gastro-oesophageal cancer, alongside Rylaze, Zepzelca (lurbinectedin) and CPX-351 for acute myeloid leukaemia. Whether zanidatamab can grow from a rare bile duct indication into gastric cancer is its open question.

## Summary

Jazz Pharmaceuticals, based in Dublin and listed as JAZZ, commercialises zanidatamab, sold as Ziihera, outside Asia, in biliary tract and gastro-oesophageal cancer. Its oncology portfolio also includes Rylaze asparaginase and Zepzelca, or lurbinectedin, partnered with PharmaMar, along with CPX-351 for acute myeloid leukaemia, defibrotide and dordaviprone. OnCo links it to biliary tract, gallbladder and gastric cancer, acute myeloid leukaemia and Ewing sarcoma, and to Zai Lab as a partner. Whether zanidatamab can expand from a rare HER2-positive bile duct indication into gastric cancer at scale is the open question. Zanidatamab has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Dublin
- Type: biotech
- Website: https://www.jazzpharma.com
- Ticker: JAZZ

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Jazz_Pharmaceuticals
- Official website: https://www.jazzpharma.com

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)](https://onco.cc/drugs/asparaginase/), [CPX-351 (liposomal daunorubicin-cytarabine)](https://onco.cc/drugs/cpx-351/), [Crisantaspase (recombinant Erwinia asparaginase)](https://onco.cc/drugs/crisantaspase/), [Defibrotide](https://onco.cc/drugs/defibrotide/), [Dordaviprone](https://onco.cc/drugs/dordaviprone/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/), [Zanidatamab](https://onco.cc/drugs/zanidatamab/)
- trials: [A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer](https://onco.cc/trials/nct07102381/), [A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors](https://onco.cc/trials/nct06695845/), [A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o](https://onco.cc/trials/nct06435429/), [A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC](https://onco.cc/trials/nct07459634/), [ACTION](https://onco.cc/trials/action-dmg/), [ATLANTIS](https://onco.cc/trials/atlantis/), [Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.](https://onco.cc/trials/nct07192068/), [CPX-351 Study 301](https://onco.cc/trials/cpx-351-301/), [HERIZON-BTC-01](https://onco.cc/trials/herizon-btc-01/), [HERIZON-BTC-302](https://onco.cc/trials/herizon-btc-302/), [HERIZON-GEA-01](https://onco.cc/trials/herizon-gea-01/), [IMforte](https://onco.cc/trials/imforte/), [Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer](https://onco.cc/trials/nct07153055/), [PRE-ISPY Phase I/II Oncology Platform Program](https://onco.cc/trials/nct05868226/), [Study 2005-01](https://onco.cc/trials/study-2005-01/), [Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma](https://onco.cc/trials/nct05734066/), [Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma](https://onco.cc/trials/nct07282587/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/)
- key papers: [Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure](https://onco.cc/key-papers/paper-defibrotide-2005-01-blood-2016/), [Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study](https://onco.cc/key-papers/paper-harding-lancet-oncol/)
- companies: [Zai Lab](https://onco.cc/companies/zai-lab/)

---
JSON: https://onco.cc/api/v1/entities/jazz.json